Atrys Health (XMAD:ATRY) OCF Margin %: -6.67% (As of Dec. 2025)

What is Atrys Health OCF Margin %?

Atrys Health XMAD:ATRY -0.97% 66 OCF Margin % is -6.67% as of Dec. 2025. GuruFocus rates XMAD:ATRY with a GF Score™ of 66/100 and a GF Value™ of €3.11 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, Atrys Health ranks better than 67.81% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Atrys Health's Cash Flow from Operations for the six months ended in Dec. 2025 was €-4.7 Mil. Atrys Health's Revenue for the six months ended in Dec. 2025 was €69.9 Mil. Therefore, Atrys Health's OCF Margin % for the quarter that ended in Dec. 2025 was -6.67%.

As of today, Atrys Health's current OCF Yield % is -0.80%.

The historical rank and industry rank for Atrys Health's OCF Margin % or its related term are showing as below:

XMAD:ATRY' s OCF Margin % Range Over the Past 10 Years
Min: -17.41 Med: 0.6 Max: 21.82
Current: -0.84

During the past 10 years, the highest OCF Margin % of Atrys Health was 21.82%. The lowest was -17.41%. And the median was 0.60%.

XMAD:ATRY's OCF Margin % is ranked better than
67.81% of 960 companies
in the Biotechnology industry
Industry Median: -68.59 vs XMAD:ATRY: -0.84

Atrys Health OCF Margin % Related Terms

Atrys Health OCF Margin % Historical Data

* Premium members only.

The historical data trend for Atrys Health's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health OCF Margin % Chart

Atrys Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

3.88

-9.75

2.83

2.31

-1.11

Atrys Health Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
OCF Margin %	Get a 7-Day Free Trial															13.55	-15.99	30.00	2.68	-6.67

XMAD:ATRY vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Atrys Health's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrys Health OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Atrys Health's OCF Margin % falls into.

Save Embed

66GF Score

Atrys Health SA XMAD:ATRY

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Atrys Health OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Atrys Health's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-1.559	/	141.007
	=	-1.11 %

Atrys Health's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	-4.667	/	69.945
	=	-6.67 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -6.67% mean?

Atrys Health (XMAD:ATRY) has a OCF Margin % of -6.67% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Atrys Health and its competitors. According to the industry distribution chart, Atrys Health ranks #309 out of 960 companies in the Biotechnology industry, placing it in the top 32.2%.

Is Atrys Health's OCF Margin % too high?

Atrys Health's current OCF Margin % is -6.67%. Based on the distribution chart, Atrys Health ranks #309 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Atrys Health's OCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Atrys Health ranks #309 out of 960 companies for OCF Margin %. This puts Atrys Health in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Atrys Health and its competitors. Atrys Health's current OCF Margin % is -6.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Atrys Health stock overvalued right now?

Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.57 — trading 17.5% below its estimated fair value. The current OCF Margin % is -6.67%. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current OCF Margin % is -6.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.57 is trading 17.5% below its estimated GF Value™ of €3.11. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

OCF Margin %: -6.67%
GF Value™: €3.11 vs. price of €2.57 (17.5% below fair value)
GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Industry Healthcare Biotechnology

Comparable Companies XMAD:ORY XMAD:VYT XMAD:BST VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX BNTX INSM ROIV INCY MRNA HKSE:01801

Other Exchanges A2T:Germany

Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025

Website https://www.atryshealth.com

Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.

66GF Score

Get the complete analysis for XMAD:ATRY

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.57

Price

€3.11

GF Value

View XMAD:ATRY Analysis

See OCF Margin % data for all stocks →